Figure 1.
Analysis of serum cytokine levels and blood parameters upon anti–IL-6 Ab treatment. JAK2+/V617F mice were treated 3 times per week over 3 weeks with 200 μg of anti-IL6 Ab per injection (MP5-20F3; BioXcell; n = 5) and IgG control (HRPN; BioXcell; n = 7). (A) The cytokine levels in serum of treated and untreated (n = 10) mice were measured by Eve Technologies Corporation (Mouse Cytokine Array/Chemokine Array 31-Plex). Cytokine level changes are shown as a heatmap according to the JAK2+/V617F level (left) and were sorted by reduction of cytokine level by anti–IL-6 Ab treatment. Additionally, cytokines with distinct changes are shown as a scatter blot (right). (B-I) Retrobulbarly collected peripheral blood of treated and untreated mice was analyzed using the ADVIA 2120i Hematology System. Samples indicating Hct (B), RBC count (C), mean corpuscular volume (MCV) (D), platelets (PLT) (E), WBC count (F), lymphocyte (G), neutrophil granulocyte (H), and monocyte counts (I) are depicted at start and end point of anti–IL-6 Ab (n = 9) and IgG (n = 9) treatment of JAK2+/V617F mice. *P < .05, **P < .01, nonsignificant (ns) P > .05 (by nonparametric, 2-tailed Mann-Whitney test). IFN, interferon; G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor.

Analysis of serum cytokine levels and blood parameters upon anti–IL-6 Ab treatment. JAK2+/V617F mice were treated 3 times per week over 3 weeks with 200 μg of anti-IL6 Ab per injection (MP5-20F3; BioXcell; n = 5) and IgG control (HRPN; BioXcell; n = 7). (A) The cytokine levels in serum of treated and untreated (n = 10) mice were measured by Eve Technologies Corporation (Mouse Cytokine Array/Chemokine Array 31-Plex). Cytokine level changes are shown as a heatmap according to the JAK2+/V617F level (left) and were sorted by reduction of cytokine level by anti–IL-6 Ab treatment. Additionally, cytokines with distinct changes are shown as a scatter blot (right). (B-I) Retrobulbarly collected peripheral blood of treated and untreated mice was analyzed using the ADVIA 2120i Hematology System. Samples indicating Hct (B), RBC count (C), mean corpuscular volume (MCV) (D), platelets (PLT) (E), WBC count (F), lymphocyte (G), neutrophil granulocyte (H), and monocyte counts (I) are depicted at start and end point of anti–IL-6 Ab (n = 9) and IgG (n = 9) treatment of JAK2+/V617F mice. *P < .05, **P < .01, nonsignificant (ns) P > .05 (by nonparametric, 2-tailed Mann-Whitney test). IFN, interferon; G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal